

for rare or low prevalence complex diseases

Network

Neuromuscular Diseases (ERN EURO-NMD)

Newborn Screening in Neuromuscular Diseases

Satellite Scientific Symposium organized by ERN EURO-NMD March, 6th 2025

SMA NBS seen by patients and carers


Marie-Christine Ouillade SMA Europe



Funded by the European Union

Summary

- Acceptance of SMA NBS
- After a positive screening , the parents decision
- Patient organisation information
- The rôle of SMA Europe



Acceptance of NBS

- How is newborn screening perceived by the rare disease population?
- Eurordis Rare Barometer survey with the Screen4Care project (Eurordis, 2024)
- 6,179 people living with a rare disease and family members worldwide,
- 5,569 of whom were living in Europe
- 1,300 distinct rare diseases
- "Respondents' answers confirm the strong support for newborn screening from the rare disease community. They also show that people living with a rare disease and their family members mostly see newborn screening as a way to alleviate the burden of the diagnosis odyssey and to enable parents to make informed choices for their child living with severe and early onset conditions, regardless of their access to a treatment or intervention."
- (Eurordis, 2024)








VOICES ON NEWBORN SCREENING: The opinion of people living With a rare disease


A Rare Barometer survey with the Screen4Care project

May 2024




Acceptance of SMA NBS

- How is SMA newborn screening perceived by the public, parents, and adults with SMA?
- Boardman et al. (Boardman F. K., 2018) online survey to families affected by SMA and the UK public.
- 84% of the public were in favour of introducing SMA NBS,
 - mainly due to the belief that this would result in better health care and life expectancy for the affected infants.
- The majority of SMA adults were also in favour of newborn screening (74%) (Boardman, 2018) as were a mixed population of families and adults (70%), despite preferring pre-conception and / or prenatal screening (Boardman, 2017).



Acceptance of SMA NBS


- How is SMA newborn screening is accepted by the general population
- During the different pilots around Europe, the SMA test was proposed to parents with a short explanation of the disease
- In Germany and in France during the pilot and explicit acceptance was requested
- The rate of acceptance of the test was up to 95% by the new parents



After a positive screening


- The need of a quick answer
- The way the information is given to family is crucial
- The timeline is very short between the positive screening and the first treatment
- Around 50% of babies with 2 copies show light symptoms after 3 weeks

• Parents are requested to answer as quickly as possible




Communication

- The family is shocked
 - Less than 20% of the doctor talk is memorised
 - Importance to have a report or a paper after the first information before going back home
 - The annoncement must be absolutly different from the usual way to announce SMA
- Few family doctors are able to give answers to the family
 - Importance of a contact between the center of excellence and the local doctor
- Patient organisation are rarely contacted at this stage
- Very poor information about presymptomatic on internet
 - Risk of misunderstanding



Google



Conseil : Affichez les résultats en français. Vous pouvez aussi en savoir plus sur le filtrage par langue.

SMA : le Zolgensma est plus efficace en présymptomatique. Les résultats de l'essai SPR1NT montrent que traiter par le Zolgensma avant l'apparition des symptômes dans la SMA est plus efficace qu'après. De nouvelles preuves en faveur du dépistage néonatal de cette maladie. 18 juil. 2022

*

AFM Téléthon

https://www.afm-telethon.fr > actualites > sma-le-zolgens...

SMA : le Zolgensma est plus efficace en présymptomatique

À propos des extraits optimisés • Commentaires



National Institutes of Health (NIH) (.gov) https://pubmed.ncbi.nlm.nih.gov > ... • Traduire cette page

Systematic Review of Presymptomatic Treatment for Spinal ...

de K Cooper · 2024 · Cité 2 fois — This systematic review synthesises findings from prospective studies of presymptomatic treatment for 5q SMA published up to December 2023.

Institut de Myologie https://www.institut-myologie.org > Actualités

Traiter en présymptomatique la SMA avec quatre copies de ...

9 juin 2022 — la frontière entre état présymptomatique et symptomatique est ténue, surtout pour des pédiatres moins experts de la pathologie. Quant au choix ...



Zolgensma

https://www.zolgensma.com > pre... · Traduire cette page

Presymptomatic SMA - SPR1NT clinical study results

ZOLGENSMA is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time ...



National Institutes of Health (NIH) (.gov)

https://pmc.ncbi.nlm.nih.gov > PM... · Traduire cette page

Systematic Review of Presymptomatic Treatment for Spinal ...

de K Cooper · 2024 · Cité 2 fois - Spinal muscular atrophy (SMA) causes the degeneration of motor neurons in the spinal cord. Treatments including nusinersen, risdiplam, and onasemnogene ..

SPINRAZA® (nusinersen)

https://www.spinraza.com > home Traduire cette page



Presymptomatic SMA Study

Super: In an ongoing supportive study, 25 infants who had not yet shown symptoms of



presymptomatic SMA types and treatments

Produits Vidéos courtes Actualités Livres Tous Images Vidéos



National Institutes of Health (NIH) (.gov)

https://pmc.ncbi.nlm.nih.gov > PM... · Traduire cette page

Systematic Review of Presymptomatic Treatment for Spinal ...

de K Cooper · 2024 · Cité 2 fois — Three single-arm interventional studies assessed three different presymptomatic SMA treatments (nusinersen, onasemnogene abeparvovec, and risdiplam). In the ...

Autres questions

How do you treat presymptomatic SMA?

Treatments including nusinersen, risdiplam, and onasemnogene abeparvovec have been shown to be effective in reducing symptoms, with recent studies suggesting greater effectiveness when treatment is initiated in the presymptomatic stage. 14 août 2024




PubMed

https://pubmed.ncbi.nlm.nih.gov > ...

Systematic Review of Presymptomatic Treatment for Spinal Muscular ...

What are the 4 types of SMA?

There are four types of SMA.






The rôle of Patient Organisation in communication


- Very few families contact the PO for a support on decision
- The contact arrives later with questions about the future development of the disaeses
- The Polish information paper





The role of SMA Europe

- How a patient organisation can accelerate the implementation of SMA NBS
- July 2020 creation of the NBS SMA Alliance
 - Creation of tools
 - Webinar
 - Scientific conferences
 - The white paper
- End of 2024 72% of the newborns are tested in Europe
- Harmonisation of practices – ENMC meeting



Contents lists available at ScienceDirect

Neuromuscular Disorders


journal homepage: www.elsevier.com/locate/nmd

270th ENMC International Workshop: Consensus for SMN2 genetic analysis in SMA patients 10–12 March, 2023, Hoofddorp, the Netherlands

Emanuela Abiusi^{a,1}, Mar Costa-Roger^{b,1}, Enrico Silvio Bertini^{c,2,*}, Francesco Danilo Tiziano^{a,d,2,*}, Eduardo F. Tizzano^{b,2,*}, on behalf of all participants³

White Paper 2024

Spinal muscular atrophy: Screen at birth, save lives



MA Alliance



EUR


^a Section of Genomic Medicine, Department of Public Health and Life Sciences, Università Cattolica del Sacro Cuore, Roma, Italy ^b Clinical and Molecular Genetics Area, Vall d'Hebron Hospital; Medicine Genetics Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain

^c Research Unit of Neuromuscular Disease, Bambino Gesu' Children's Hospital, IRCCS, Roma, Italy

^d Complex Unit of Medical Genetics, Fondazione Policlinico Universitario IRCCS "A. Gemelli", Roma, Italy

Thank for your attention





SMA EUR OPE

